Terms: = Pancreatic cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Clinical Outcome
266 results:
1. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract] [Full Text] [Related]
2. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract] [Full Text] [Related]
3. Optimal Follow-up of Incidental pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
[TBL] [Abstract] [Full Text] [Related]
4. Response of Locally Advanced pancreatic cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and clinical outcome.
Sharma NR; Lo SK; Hendifar A; Othman MO; Patel K; Mendoza-Ladd A; Verco S; Maulhardt HA; Verco J; Wendt A; Marin A; Schmidt CM; diZerega G
Pancreas; 2023 Mar; 52(3):e179-e187. PubMed ID: 37782888
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Militello AM; Orsi G; Cavaliere A; Niger M; Avallone A; Salvatore L; Tortora G; Rapposelli IG; Giordano G; Noventa S; Giommoni E; Bozzarelli S; Macchini M; Peretti U; Procaccio L; Puccini A; Cascinu S; Montagna C; Milella M; Reni M
Cancer Chemother Pharmacol; 2023 Dec; 92(6):501-510. PubMed ID: 37725113
[TBL] [Abstract] [Full Text] [Related]
6. Real time
Kim DW; Beato F; Kim Y; Tassielli AF; Dai R; Denbo JW; Hodul PJ; Malafa MP; Fleming JB
Oncotarget; 2023 Sep; 14():811-818. PubMed ID: 37713330
[TBL] [Abstract] [Full Text] [Related]
7. The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: "Standing on the Shoulders of Giants".
Zwart MJW; van den Broek B; de Graaf N; Suurmeijer JA; Augustinus S; Te Riele WW; van Santvoort HC; Hagendoorn J; Borel Rinkes IHM; van Dam JL; Takagi K; Tran KTC; Schreinemakers J; van der Schelling G; Wijsman JH; de Wilde RF; Festen S; Daams F; Luyer MD; de Hingh IHJT; Mieog JSD; Bonsing BA; Lips DJ; Abu Hilal M; Busch OR; Saint-Marc O; Zeh HJ; Zureikat AH; Hogg ME; Koerkamp BG; Molenaar IQ; Besselink MG;
Ann Surg; 2023 Dec; 278(6):e1232-e1241. PubMed ID: 37288547
[TBL] [Abstract] [Full Text] [Related]
8. pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
[TBL] [Abstract] [Full Text] [Related]
9. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine.
D'Angelo A; Catalano M; Conca R; Petrioli R; Siminonato F; Cappetta A; Roviello G; Ramello M
J Chemother; 2023 Dec; 35(8):753-759. PubMed ID: 37167100
[TBL] [Abstract] [Full Text] [Related]
11. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract] [Full Text] [Related]
12. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract] [Full Text] [Related]
13. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
[TBL] [Abstract] [Full Text] [Related]
14. [clinical outcome of Robot-Assisted Distal Pancreatectomy in Our Institutional Introduction].
Matsukawa H; Satoh D; Ishida M; Yoshimoto M; Idani H; Shirakawa Y; Nakano K; Yoshimitsu M; Choda Y; Yano T; Sawada H; Katsura Y; Okura T; Fukuhara S; Shiozaki S
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1671-1672. PubMed ID: 36733171
[TBL] [Abstract] [Full Text] [Related]
15. clinical outcome and Treatment Sequences of Patients with Advanced pancreatic cancer Treated with Contemporary Chemotherapy Protocols.
Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
[TBL] [Abstract] [Full Text] [Related]
16. outcomes of feeding jejunostomy after pancreaticoduodenectomy: A single-center experience.
Yamamoto N; Aoyama T; Murakawa M; Kamiya M; Shiozawa M; Rino Y; Masuda M; Morinaga S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S444-S448. PubMed ID: 36511001
[TBL] [Abstract] [Full Text] [Related]
17. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
[TBL] [Abstract] [Full Text] [Related]
18. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
[TBL] [Abstract] [Full Text] [Related]
19. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer.
Krebs N; Klein L; Wegwitz F; Espinet E; Maurer HC; Tu M; Penz F; Küffer S; Xu X; Bohnenberger H; Cameron S; Brunner M; Neesse A; Kishore U; Hessmann E; Trumpp A; Ströbel P; Brekken RA; Ellenrieder V; Singh SK
JCI Insight; 2022 Aug; 7(16):. PubMed ID: 35993361
[TBL] [Abstract] [Full Text] [Related]
20. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
[Next]
